| Population 2016 |
103 million |
| |
| | | | | |
| Estimates of TB burden*, 2016 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
22 |
(22–22) |
21 |
(21–22) |
| Mortality (HIV+TB only) |
0.3 |
(0–2.6) |
0.29 |
(0–2.5) |
| Incidence (includes HIV+TB) |
573 |
(321–895) |
554 |
(311–866) |
| Incidence (HIV+TB only) |
6 |
(2.5–11) |
5.9 |
(2.4–11) |
| Incidence (MDR/RR-TB)** |
30 |
(21–40) |
30 |
(20–39) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2016 |
| |
0-14 years |
> 14 years |
Total |
| Females |
33 |
(16–50) |
136 |
(68–205) |
169 |
(84–255) |
| Males |
37 |
(18–56) |
366 |
(182–550) |
403 |
(200–606) |
| Total |
70 |
(35–106) |
502 |
(249–755) |
573 |
(321–895) |
| |
| | | | | |
| TB case notifications, 2016 |
|
| Total cases notified |
345 144 |
| Total new and relapse |
332 941 |
| - % tested with rapid diagnostics at time of diagnosis |
13% |
| - % with known HIV status |
19% |
| - % pulmonary |
98% |
| - % bacteriologically confirmed among pulmonary |
37% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2016 |
58% (37–100) |
| TB patients facing catastrophic total costs, 2017 |
35% |
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 |
0.04 (0.02–0.06) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2016 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
1 009 |
2% |
| - on antiretroviral therapy |
820 |
81% |
| |
| | | | | |
| Drug-resistant TB care, 2016 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
20 000
(15 000–24 000) |
| Estimated % of TB cases with MDR/RR-TB |
2.6% (1.8–3.3) |
29% (20–38) |
|
| % notified tested for rifampicin resistance |
7% |
67% |
50 752 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
432 |
| Laboratory-confirmed cases |
MDR/RR-TB: 5 233, XDR-TB: 5 |
| Patients started on treatment **** |
MDR/RR-TB: 5 253, XDR-TB: 5 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2015 |
91% |
263 481 |
| Previously treated cases, excluding relapse, registered in 2015 |
82% |
7 925 |
| HIV-positive TB cases registered in 2015 |
65% |
277 |
| MDR/RR-TB cases started on second-line treatment in 2014 |
46% |
2 490 |
| XDR-TB cases started on second-line treatment in 2014 |
0% |
7 |
| |
| | | | | |
| TB preventive treatment, 2016 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
49% |
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
5% (4.6–5.5) |
| |
| | | | | |
| TB financing, 2017 |
|
| National TB budget (US$ millions) |
104 |
| Funding source: 19% domestic, 53% international, 28% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed | | |
| | | | | |